2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1887

Olfactory Impairment Is Associate with Cognitive Dysfunction and Regional Brain Atrophy in Systemic Sclerosis
Abstract Number: 1888

Reliability, Validity, and Sensitivity to Change of the Simplified Duruoz Hand Index in Systemic Sclerosis
Abstract Number: 1889

Predictors of Acro-Osteolysis in Systemic Sclerosis
Abstract Number: 1890

Functional Disability and Its Predictors in Systemic Sclerosis: A Study from the Desscipher Project within the European Scleroderma Trials and Research Group
Abstract Number: 1891

Excellent Reliability of Semiquantitative Nailfold Capillaroscopy Assessment in a Systemic Sclerosis Cohort – a Pilot Study
Abstract Number: 1892

Immunosignature Technology Differentiates Patients with Systemic Sclerosis and Internal Organ Involvement
Abstract Number: 1893

Prevalence of Antiphospholipid Antibodies in Systemic Sclerosis: A Systematic Review and Meta-Analysis
Abstract Number: 1894

Increased Mortality in Systemic Sclerosis Patients with Fibrosing Myopathy
Abstract Number: 1895

Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Abstract Number: 1896

Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases
Abstract Number: 1897

Vitamin-D Levels and Gastrointestinal (GI) Manifestations in Systemic Sclerosis (SSc)
Abstract Number: 1898

The Lack of Association of Osteoporosis with Proton Pump Inhibitor in Scleroderma: A UK Single Centre Cohort Experience
Abstract Number: 1899

The Intestinal Involvement in Systemic Sclerosis Is Characterized By a Peculiar Gut Microbiota
Abstract Number: 1900

Anti-Topoisomerase Positive Systemic Sclerosis – Prognosis Infaust?
Abstract Number: 1901

Screening for Pulmonary Arterial Hypertension in an Unselected Prospective Systemic Sclerosis Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].